Discover why Bristol-Myers Squibb's undervalued stock, strong cash flow, and 5% dividend yield make it an attractive buy ...

Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

Looking into the current session, Bristol-Myers Squibb Inc. BMY shares are trading at $47.05, after a 1.22% drop. Over the ...

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Bristol Myers Squibb (BMY) closed at $47.51 in the latest trading session, marking a +2.64% move from the prior day.

Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse ...

This Big Pharma company is positioned for a rebound while continuing to pay investors a sizable dividend yield.

Cantor Fitzgerald maintained its neutral rating and $55.00 price target on Bristol-Myers Squibb Co. (NYSE: NYSE: BMY) Thursday, closely matching InvestingPro ’s Fair Value estimate.

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, Bristol Myers is expected ...

Bristol-Myers Squibb (NYSE:BMY) recently announced dividend declarations for common and preferred stock, potentially adding some weight to the company's stock performance over the past month. The ...